Amineo

Amineo is a spin-off of INRAE, CNRS and INSA, specialized in the computational protein design. The company will be founded in June 2022 by Sophie Barbe, Thomas Schiex and Juan Cortés with the aim of designing proteins with optimized and new capacities for biotechnology and health, by leveraging proprietary algorithms developed by co-founders.

The development of new useful proteins remains slow, difficult and costly, whether in health or biotechnology fields. Amineo brings disruptive approaches allowing to accelerate and reduce the costs of developing new proteins or improving the performance of existing proteins. Amineo’s unique technologies build on 15 years of academic research conducted by co-founders at TBI, MIAT and LAAS. With significant advantages in terms of applicability, speed and accuracy, these technologies drastically reduces the need for costly and time-consuming experiments. They offer a radical change for the development of all types of optimized or new proteins: enzymes, antibodies and other "binders", macromolecular assemblies, peptides, etc. These protein design technologies combine molecular modeling methods with advanced machine learning and reasoning algorithms. Important properties of proteins can be targeted by these technologies to achieve a protein that meets the requirements of the intended uses in health or biotechnology.